专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20110086040A1 METHOD OF TREATING HEMOLYTIC DISEASE 审中-公开
标题翻译：治疗HEMOLYTIC疾病的方法
公开(公告)号：US20110086040A1
公开(公告)日：2011-04-14
申请号：US12902617
申请日：2010-10-12
申请人： Leonard Bell , Russell P. Rother
发明人： Leonard Bell , Russell P. Rother
IPC分类号： A61K39/395 , A61P7/00
CPC分类号： A61K45/06 , A61K39/39541 , A61K2039/545 , A61K2300/00
摘要： Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.
摘要翻译：使用结合或以其它方式阻断一种或多种补体成分（例如补体抑制性抗体）的产生和/或活性的化合物治疗阵发性夜间血红蛋白尿或其它溶血性疾病。

52. 发明申请

US20110002931A1 BISPECIFIC ANTIBODIES THAT BIND TO COMPLEMENT PROTEINS 审中-公开
标题翻译：双重补充蛋白质的双重抗体
公开(公告)号：US20110002931A1
公开(公告)日：2011-01-06
申请号：US12820654
申请日：2010-06-22
申请人： Paul P. Tamburini
发明人： Paul P. Tamburini
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28 , A61P11/06 , A61P19/02 , A61P21/04 , A61P3/10 , A61P7/06 , A61P17/06 , A61P25/00
CPC分类号： C07K16/2896 , C07K16/18 , C07K2317/31 , C07K2317/94
摘要： The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1 or C5L2), the C5b-9 complex, and a component or intermediate of terminal complement such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein are useful for, e.g., inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 complex) and/or C5a anaphylatoxin-mediated inflammation (e.g., C5a-mediated chemotaxis of inflammatory immune cells). Accordingly, the bispecific antibodies can be used in methods for treating a variety of complement pathway-associated disorders.
摘要翻译：本公开涉及可以结合两个或多个不同表位的双特异性抗体。例如，本文所述的双特异性抗体可以结合两种或更多种不同的蛋白质，其中至少两种蛋白质选自C5a，C5b，C5a的细胞受体（例如C5aR1或C5L2），C5b-9复合物，和末端补体的成分或中间体如C5b-6，C5b-7或C5b-8。本文所述的双特异性抗体可用于例如抑制末端补体（例如，C5b-9复合物的组装和/或活性）和/或C5a过敏毒素介导的炎症（例如，C5a介导的炎性免疫细胞趋化性）。因此，双特异性抗体可用于治疗各种补体途径相关疾病的方法。

53. 发明申请

US20100285030A1 Antibodies to Ox-2/Cd200 and Uses Thereof 有权
标题翻译： Ox-2 / Cd200的抗体及其用途
公开(公告)号：US20100285030A1
公开(公告)日：2010-11-11
申请号：US12087683
申请日：2007-01-11
申请人： Katherine S. Bowdish , Anke Kretz-Rommel , Susan Faas McKnight , Jeremy P. Springhorn , Dayang Wu
发明人： Katherine S. Bowdish , Anke Kretz-Rommel , Susan Faas McKnight , Jeremy P. Springhorn , Dayang Wu
IPC分类号： A61K39/395 , C07K16/28 , A61K38/02 , A61K31/7088 , A61K33/00 , G01N33/566 , A61P35/00 , A61P31/12
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/73
摘要： This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
摘要翻译：本申请提供了用于调节和/或消耗CD200阳性细胞的方法和组合物。

54. 发明申请

US20100239598A1 POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF 有权
标题翻译：来自慢性淋巴细胞白血病细胞的多肽和抗体及其用途
公开(公告)号：US20100239598A1
公开(公告)日：2010-09-23
申请号：US12715303
申请日：2010-03-01
申请人： Katherine S. Bowdish , John McWhirter , Anke Kretz-Rommel , Toshiaki Maruyama
发明人： Katherine S. Bowdish , John McWhirter , Anke Kretz-Rommel , Toshiaki Maruyama
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
摘要翻译：癌症治疗使用以下疗法：1）干扰CD200与其受体之间的相互作用以阻断免疫抑制，从而促进根除癌细胞; 和2）通过补体介导或抗体依赖性细胞毒性直接杀死癌细胞，或通过使用包含CD200靶向部分的融合分子靶向细胞。治疗包括施用新型抗体，其功能片段或含有其部分的融合分子。

55. 发明申请

US20100196374A1 METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE 有权
标题翻译：治疗自发性疾病的方法和组合
公开(公告)号：US20100196374A1
公开(公告)日：2010-08-05
申请号：US12452772
申请日：2008-07-25
申请人： Yi Wang
发明人： Yi Wang
IPC分类号： A61K39/395 , A61P29/00 , A61P37/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/76
摘要： The disclosure relates to OX-2/CD200 (herein referred to as CD200) antibodies and methods of treating autoimmune disease.
摘要翻译：本公开涉及OX-2 / CD200（本文称为CD200）抗体和治疗自身免疫性疾病的方法。

56. 发明申请

US20100135992A1 Prolongation of Survival of an Allograft by Inhibiting Complement Activity 审中-公开
标题翻译：通过抑制补体活性延长同种异体移植物的存活
公开(公告)号：US20100135992A1
公开(公告)日：2010-06-03
申请号：US12224567
申请日：2007-03-02
申请人： Russell P. Rother , Hao Wang , Zheng Zhong
发明人： Russell P. Rother , Hao Wang , Zheng Zhong
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K16/18 , A61K31/16 , A61K31/365 , A61K31/573 , A61K38/13 , A61K2039/505
摘要： Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allograft recipient an inhibitor of complement activity together with one or more immunosuppressants and/or immunosuppressive methods. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.
摘要翻译：提出了延长移植细胞，组织或器官存活的方法。这些方法涉及向同种异体移植受体施用补体活性的抑制剂以及一种或多种免疫抑制剂和/或免疫抑制方法。补体活性抑制剂长期施用。已经确定了这些方法以帮助预防同种异体移植物的慢性排斥反应。这些方法可以另外用于接受者已经被同化异体移植或同种异体移植物与受体之间存在ABO不匹配的情况。

57. 发明授权

US07598353B2 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof 有权
公开(公告)号：US07598353B2
公开(公告)日：2009-10-06
申请号：US12221134
申请日：2008-07-30
申请人： Katherine S. Bowdish , John McWhirter , Anke Kretz-Rommel , Toshiaki Maruyama
发明人： Katherine S. Bowdish , John McWhirter , Anke Kretz-Rommel , Toshiaki Maruyama
IPC分类号： C12P21/08
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.

58. 发明授权

US07598030B2 Antibodies against cancer produced using masked cancer cells as immunogen 失效
标题翻译：使用掩蔽的癌细胞作为免疫原产生抗癌的抗体
公开(公告)号：US07598030B2
公开(公告)日：2009-10-06
申请号：US11631910
申请日：2005-07-08
申请人： Katherine S. Bowdish , Hong Xin , Toshiaki Maruyama , Naveen Dakappagari
发明人： Katherine S. Bowdish , Hong Xin , Toshiaki Maruyama , Naveen Dakappagari
IPC分类号： G01N1/70 , G01N33/53 , G01N33/567
CPC分类号： C07K16/3069 , A61K2039/505 , C07K16/00 , C07K16/2896
摘要： This disclosure relates to methods for selecting antibodies having desirable characteristics from a population of diverse antibodies. More specifically, this disclosure provides methods for identifying antibodies which bind to cancer cells, but which do not bind to human red or white blood cells or normal tissue cells. Antibodies of the disclosure can be used for therapeutic and/or diagnostic purposes.
摘要翻译：本公开涉及从不同抗体群体中选择具有所需特征的抗体的方法。更具体地，本公开提供了用于鉴定结合癌细胞但不结合人红细胞或白细胞或正常组织细胞的抗体的方法。本公开的抗体可用于治疗和/或诊断目的。

59. 发明申请

US20090022745A1 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof 有权
公开(公告)号：US20090022745A1
公开(公告)日：2009-01-22
申请号：US12221134
申请日：2008-07-30
申请人： Katherine S. Bowdish , John McWhirter , Anke Kretz-Rommel , Toshiaki Maruyama
发明人： Katherine S. Bowdish , John McWhirter , Anke Kretz-Rommel , Toshiaki Maruyama
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.

60. 发明授权

US07405279B2 Chimeric proteins for diagnosis and treatment of diabetes 失效
标题翻译：用于糖尿病诊断和治疗的嵌合蛋白
公开(公告)号：US07405279B2
公开(公告)日：2008-07-29
申请号：US11143966
申请日：2005-06-03
申请人： Yi Wang , John Mueller , Louis A. Matis
发明人： Yi Wang , John Mueller , Louis A. Matis
IPC分类号： C07K14/62 , C07K14/435 , A61K38/17 , A61K38/28 , A61K38/43
CPC分类号： C07K14/62 , A61K38/00 , C07K2319/00 , C12N9/88 , C12Y401/01015 , Y10S514/866
摘要： Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.
摘要翻译：提供了包含GAD和胰岛素的免疫显性表位的新型嵌合融合蛋白。还提供了用于预防和治疗1型糖尿病的这种蛋白质的免疫调节方法。本发明的嵌合融合蛋白可用于预测1型糖尿病发病的风险，确定疾病进展早期1型糖尿病患者的预后，以及评估患者作为胰腺细胞或组织移植受体的适应性。根据本发明的免疫调节方法施用本发明的蛋白质对患有或预测具有发展中的1型糖尿病风险的患者的疾病发展和严重性以及移植的结果产生有益的影响的胰腺细胞或组织在1型糖尿病患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式